Alpharma withdraws painkiller NDA

Alpharma has withdrawn its NDA for Embeda, its extended-release painkiller. While the company's drug qualified for priority review, Alpharma said that "certain technical issues around data presentation" prevented the FDA from evaluating the drug in the six month review time. There were no details on exactly what those technical issues were. Alpharma said it plans to quickly resolve the issues, re-submit the NDA and launch the drug in the first quarter of 2009.

In its most recent Phase III trial, Embeda demonstrated significant pain relief. The painkiller is designed to be effective when taken as directed, but if tampered with by a drug abuser, the feeling of euphoria is dampened.

- see Alpharma's release

Related Articles:
Alpharma touts Phase III pain drug data
Alpharma sub inks $202M deal for pain drug
Alpharma to proceed with painkiller trial
Investors bid up Alpharma stock on rumors of a sale

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.